Weekly Digests
‹ Back to February

Adding a personalized neoantigen vaccine to checkpoint blockade keeps resected melanoma away in a phase IIb trial

February 7, 2024

Following surgical resection of high-risk cutaneous melanoma, patients are generally treated with checkpoint inhibitors to prevent tumor recurrence, but a high proportion of patients still recur within 5 years. In an effort to reduce these recurrence rates, Weber et al. evaluated the addition of adjuvant personalized neoantigen vaccines (mRNA-4157) in a phase IIb clinical trial. The results were recently published in The Lancet.

Made using the same mRNA vaccine platform that is implemented for the SARS-CoV-2 (COVID-19) vaccine, RNA-4157 is an mRNA-based individualized neoantigen therapy. Based on samples of tumor and healthy tissue, researchers identify a patient’s HLA type and their tumor’s unique neoantigens, encode up to 34 neoantigens in mRNA, and encapsulate that mRNA in lipid nanoparticles. In preclinical work and a phase I study, mRNA-4157 was shown to induce robust antigen-specific T cell responses to encoded neoantigens, and to enhance antitumor responses in combination with pembrolizumab in the adjuvant setting.

In their recent phase IIb study, 157 adult patients with completely resected stage IIIB–IV melanoma, who were clinically and radiologically disease-free at the time of enrollment, were randomized to receive either mRNA-4157 plus pembrolizumab (n=107) or pembrolizumab monotherapy (n=50). Despite some holdups due to the production of COVID-19 vaccines, vaccine manufacturing was feasible, with only one patient for whom a vaccine could not be manufactured due to insufficient tissue. Patients in both the monotherapy and combination groups received 200mg of pembrolizumab intravenously every 3 weeks for up to 18 doses; the average time from surgery to the first dose of pembrolizumab was 10 weeks. For patients in the vaccine treatment group, 1mg of mRNA-4157 was given intramuscularly on the same days as the pembrolizumab for up to 9 doses, starting at the earliest availability of the vaccine, with 81% of patients beginning at pembrolizumab cycle three, 11% at cycle four, and 9% at cycle five. A majority of patients had protocol variations, largely due to disruptions related to the COVID-19 pandemic.

For this trial, the primary endpoint was recurrence-free survival, which was defined as the time from the first dose of pembrolizumab to the date of first recurrence (which could be local, regional, or a distant metastasis), a new primary melanoma, or death from any cause. At a median follow-up of 23 months for the combination group and 24 months for the monotherapy group, recurrence-free survival was longer in the combination group. Looking at recurrence-free survival over time, the 12-month recurrence-free survival rates were 83% in the combination group and 77% in the monotherapy group, and the respective 18-month recurrence-free survival rates were 79% and 62%. At the time of data cutoff, the recurrence free-survival rates were 78% and 60%.

Since most first recurrences are distant metastases, a secondary endpoint of this trial was distant metastasis-free survival, which like recurrence-free survival, was longer in the combination group compared to the monotherapy group. At 12 months, the distant metastasis-free survival rates were 93% and 89%, respectively. Over time, that gap widened, with 18-month distant metastasis-free survival rates of 92% and 77%, and 24-month distant metastasis-free survival rates of 92% and 73%. Further, a higher proportion of patients in the monotherapy group had a distant recurrence event as their recurrence-free survival event compared with the combination group. These results suggest that patients treated with mRNA-4157 had a reduced or delayed risk of disease recurrence at distant sites, and that mRNA-4157 likely improves outcomes by mediating protection against distant metastases over time.

Another secondary endpoint of this trial was safety and tolerability. Among all patients included in the safety analysis (n=154), most treatment-related adverse events were grade 1–2, with 100% of patients in the combination group and 83% of patients in the monotherapy group reporting adverse events of some kind. The most common adverse events related to the mRNA-4157 were fatigue, chills, and injection site pain/reactions. Grade 3 or higher treatment-related adverse events occurred in 25% of patients in the combination group (with 12% related to the mRNA-4157) versus 18% of patients in the monotherapy group. No grade 4 or 5 events related to the mRNA-4157 occurred, and the immune-mediated adverse event frequency was 36% in both groups. Adverse events related to pembrolizumab were consistent with its use as a monotherapy. These results indicate a higher rate of mostly low-grade adverse events with the addition of a second agent, but treatment was considered both safe and tolerable. Further, while the most common reason to discontinue treatment in the combination treatment was adverse events, the most common reason in the monotherapy group was tumor recurrence.

Additional exploratory endpoints evaluated in this study included assessing circulating tumor DNA (ctDNA), tumor mutation burden (TMB), and PD-L1 status in baseline tumors as potential predictive biomarkers. In patients who were ctDNA-positive at baseline (minimal residual disease; n=15) versus ctDNA-negative (n=110), the researchers noted a trend towards shorter recurrence-free and distant metastasis-free survival, regardless of their treatment. TMB-high and TMB-low subgroups had a similar recurrence-free survival benefit in the combination group versus the monotherapy group, as did PD-L1-positive and PD-L1-negative subgroups, suggesting that these features are not predictive of outcomes in the combination group versus the monotherapy group for melanoma.

Overall, the results of this trial show that the addition of adjuvant mRNA-4157 to pembrolizumab in patients with resected high-risk melanoma prolonged recurrence-free survival and showed a manageable safety profile. In particular, mRNA-4157 appeared to reduce the risk of distant metastases over a prolonged period of time. An extended follow-up of this study is currently ongoing to establish the durability of the treatment effect. The combination of mRNA-4157 and pembrolizumab is also being evaluated in a phase III clinical trial.

Write-up and image by Lauren Hitchings


Weber JS, Carlino MS, Khattak A, Meniawy T, Ansstas G, Taylor MH, Kim KB, McKean M, Long GV, Sullivan RJ, Faries M, Tran TT, Cowey CL, Pecora A, Shaheen M, Segar J, Medina T, Atkinson V, Gibney GT, Luke JJ, Thomas S, Buchbinder EI, Healy JA, Huang M, Morrissey M, Feldman I, Sehgal V, Robert-Tissot C, Hou P, Zhu L, Brown M, Aanur P, Meehan RS, Zaks T. Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study. Lancet. 2024 Jan 18.

In the Spotlight...

Inhibition of CD38 enzymatic activity enhances CAR-T cell immune-therapeutic efficacy by repressing glycolytic metabolism

Across various CAR T cell models, Huang et al. found that CD38 activity played a key role in CAR T cell overactivation and exhaustion by simultaneously supporting CD38–cADPR–Ca2+ signaling (which increases NFAT activity) and limiting CD38–NAD+–SIRT1 signaling (which increases acetylated HIF1α), both of which support increased glycolysis. Chemical or genetic inhibition of CD38 enzyme activity boosted CAR T cell cytotoxicity and antitumor efficacy by reversing these effects and inhibiting glycolysis. CD38 inhibition also supported CAR T cell persistence, long-term functionality, and early differentiation towards a memory-like phenotype.

Contributed by Lauren Hitchings

Inhibition of CSF-1R and IL-6R prevents conversion of cDC2s into immune incompetent tumor-induced DC3s boosting DC-driven therapy potential

Becker et al. showed that patients with NSCLC had increased blood levels of CD1c+CD14+ DC3s expressing an immunosuppressive phenotype and reduced T cell stimulatory activity. Patients with melanoma receiving CD1c+ DC vaccines with higher CD1c+CD14+ DC levels had shorter PFS. Transcriptomic analyses showed a stronger relationship between CD1c+CD14+ cells and cDC2s than CD14+ monocytes. cDC2s, but not monocytes, were induced by tumor-derived factors to differentiate into CD1c+CD14+ cells in vitro. M-CSF and IL-6 were primary tumor drivers of CD14- to CD14+ DC conversion, and IL-6R and CSF1R inhibition blocked tumor-induced CD14+ cDC2 differentiation and enhanced T cell activation.

Contributed by Paula Hochma

T-cell Lymphoma and Secondary Primary Malignancy Risk After Commercial CAR T-cell Therapy

Of 449 patients treated with a commercial CAR T cell product (CART) at UPenn, 16 (3.6%) were diagnosed with a secondary primary malignancy at a median follow-up of 10.3 months. This included one case of secondary T cell lymphoma (TCL), which was detected 3 months after third-line axi-cel CART-19 therapy in a patient with B-cell lymphoma, unclassifiable, in one of three lymph nodes upon surgical removal of a NSCLC lesion. The TCL harbored a JAK3 variant (unknown significance) and CD8+ cytotoxic phenotype, and was defined as negative for CAR transgene integration. Ghilardi et al. concluded that risk of TCL post CART is very low, affirming the safety of commercial CART products.

Contributed by Ute Burkhardt

The efficacy of chemotherapy is limited by intratumoral senescent cells expressing PD-L2

Chaib and López-Domínguez et al. demonstrated that senescence-inducing therapies upregulated PD-L2 upon induction of senescence in different cancer cells. However, PD-L2 was not necessary for senescence induction or for the secretory phenotype of senescent cells, but it was critical for cells to evade the immune system and persist intratumorally. PD-L2-deficient tumor cells were rapidly eliminated by CD8+ T cells, did not secrete the senescence-associated chemokines CXCL1 and CXCL2, and failed to recruit myeloid-derived suppressor cells. Antibody-mediated PD-L2 blockade synergized with chemotherapy to improve immune surveillance.

Contributed by Shishir Pant

Local delivery of cell surface-targeted immunocytokines programs systemic anti-tumor immunity

Santollani et al. focused on improving the safety and efficacy of cytokine therapy by locally delivering engineered cytokines that would be retained on cells of the tumor, without systemic exposure. CD45 was abundantly expressed on immune cells and not internalized, so they designed anti-CD45-conjugated IL-12 and IL-15 immunocytokines (injected sequentially as αCD45-Cyt) and showed in multiple syngeneic mouse models that intratumoral αCD45-Cyt therapy eradicated injected tumors and untreated distal tumors. Mechanistically, αCD45-Cyt resulted in prolonged STAT5 signaling, producing potent tumor-reactive CD8+ T cells in the TME and TDLN, with a viral signature.

Contributed by Katherine Turner

Tumour-retained activated CCR7+ dendritic cells are heterogeneous and regulate local anti-tumour cytolytic activity

Lee et al. showed that CCR7+ DCs are transcriptionally heterogeneous populations, consisting of a subset that migrates to dLNs and a subset that resides in the tumor despite CCR7 expression, with the capacities to support or inhibit the cytotoxic T cell niche. Tumor-retained CCR7+ DCs acquired transcriptional features consistent with exhaustion, and co-localized with PD-1+ CD8+ T cells in human and murine solid tumors. Anti-PD-L1 treatment enhanced the expression of T cell-stimulatory molecules, promoted immunogenic CCR7+ DC–CD8+ T cell interactions, and augmented antitumor cytolytic activity, which was conserved across human cancers.

Contributed by Shishir Pant

Everything New this Week In...

Close Modal

Small change for you. Big change for us!

This Thanksgiving season, show your support for cancer research by donating your change.

In less than a minute, link your credit card with our partner RoundUp App.

Every purchase you make with that card will be rounded up and the change will be donated to ACIR.

All transactions are securely made through Stripe.